Novo Nordisk's Victoza Gains First Japanese GLP-1 Approval
This article was originally published in PharmAsia News
Executive Summary
Novo Nordisk announced Jan. 20 it received approval for Victoza (liraglutide) from Japan's Ministry of Health, Labor and Welfare for type 2 diabetes and hopes to launch Japan's first glucagon-like peptide-1 agonist in the first half of 2010 - pending pricing negotiations for National Health Insurance reimbursement
You may also be interested in...
Daiichi Sankyo, Novartis Gain MHLW Approval For Combination Hypertension Drugs
TOKYO - Daiichi Sankyo Co. and Novartis Pharma KK received Ministry of Health, Labor and Welfare approval to manufacture and distribute in Japan hypertension treatment drugs that combine angiotensin receptor blockers and calcium channel blockers, the two companies announced Jan. 20
Daiichi Sankyo, Novartis Gain MHLW Approval For Combination Hypertension Drugs
TOKYO - Daiichi Sankyo Co. and Novartis Pharma KK received Ministry of Health, Labor and Welfare approval to manufacture and distribute in Japan hypertension treatment drugs that combine angiotensin receptor blockers and calcium channel blockers, the two companies announced Jan. 20
Victoza's Regulatory Limbo Could End Shortly
FDA will provide "formal feedback" to Novo Nordisk "within weeks" about its type 2 diabetes drug, which showed a thyroid cancer signal in rodents.